Christopher Peetz
Christopher Peetz's purchase track record
Christopher Peetz has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/24/2021 | MIRM | $101K | +67.1% | +79.5% | -15.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
ARQT Highlights New ZORYVE Data, Wins Beauty Award, Faces Downgrade. Arcutis Biotherapeutics presented fresh clinical data for its topical drug ZORYVE at the EADV and Fall Clinical conferences, adding real‑world evidence on its use for inflammatory skin conditions. The company also received a 2026 Marie Claire Beauty Award for ZORYVE, highlighting its potential beyond dermatology. Meanwhile, analysts have downgraded the stock, citing a shrinking valuation multiple. These developments suggest the market is reassessing the company’s growth prospects.
Transaction History
| MIRM | ▲ Buy | Option Exercise | 5,305 | $102K | 10/6/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 6,892 | $109K | 10/6/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 30,000 | $88K | 9/1/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 21,688 | $2.1M | 9/1/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 8,312 | $815K | 9/1/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 2,300 | $230K | 8/10/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 20,000 | $59K | 8/10/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 11,683 | $1.2M | 8/10/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 6,017 | $597K | 8/10/2026 | View on chart |
| ARQT | ▲ Buy | Grant | 4,315 | $0 | 7/15/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 4,181 | $512K | 7/6/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,710 | $213K | 7/6/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 20,000 | $59K | 7/6/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 12,134 | $1.5M | 7/6/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,975 | $244K | 7/6/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 30,000 | $88K | 6/1/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 16,595 | $1.6M | 6/1/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 6,926 | $666K | 6/1/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,973 | $192K | 6/1/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 883 | $88K | 6/1/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 1,021 | $100K | 6/1/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 2,602 | $246K | 6/1/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 40,985 | $3.8M | 3/16/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 50,000 | — | 3/15/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 25,000 | — | 3/15/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 9,108 | $941K | 2/2/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 6,831 | $657K | 1/26/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 12,500 | — | 1/23/2026 | View on chart |
| MIRM | ▼ Sell | Open Market | 7,098 | $662K | 1/22/2026 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 12,797 | — | 1/21/2026 | View on chart |
| MIRM | ▼ Sell | Gift | 21,070 | $0 | 12/31/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 19,133 | $368K | 11/18/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 40,000 | $117K | 8/11/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 40,000 | $2.5M | 8/11/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 40,000 | $117K | 8/7/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 40,000 | $2.2M | 8/7/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 27,279 | $1.2M | 3/17/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 50,000 | — | 3/15/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 40,000 | $117K | 3/3/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 20,608 | $972K | 3/3/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 19,392 | $904K | 3/3/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 9,102 | $439K | 2/3/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 6,837 | $328K | 1/24/2025 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 12,500 | — | 1/23/2025 | View on chart |
| MIRM | ▼ Sell | Open Market | 7,489 | $321K | 1/7/2025 | View on chart |
| MIRM | ▲ Buy | Grant | 65 | $1K | 11/8/2024 | View on chart |
| MIRM | ▲ Buy | Option Exercise | 34,013 | $100K | 7/23/2024 | View on chart |
| MIRM | ▲ Buy | Grant | 817 | $17K | 5/10/2024 | View on chart |
| MIRM | ▼ Sell | Open Market | 6,013 | $157K | 2/2/2024 | View on chart |
| MIRM | ▼ Sell | Open Market | 5,209 | $146K | 1/8/2024 | View on chart |
| MIRM | ▼ Sell | Open Market | 5,498 | $141K | 7/3/2023 | View on chart |
| MIRM | ▲ Buy | Grant | 1,256 | $21K | 5/10/2023 | View on chart |
| MIRM | ▲ Buy | Grant | 50,000 | $0 | 1/31/2023 | View on chart |
| MIRM | ▼ Sell | Open Market | 5,159 | $106K | 1/9/2023 | View on chart |
| MIRM | ▲ Buy | Grant | 49 | $835 | 11/10/2022 | View on chart |
| MIRM | ▲ Buy | Grant | 1,500 | $20K | 5/10/2022 | View on chart |
| MIRM | ▲ Buy | Grant | 40,000 | $0 | 1/6/2022 | View on chart |
| MIRM | ▲ Buy | Open Market | 7,000 | $101K | 11/24/2021 | View on chart |
| MIRM | ▼ Sell | Open Market | 3,672 | $71K | 10/1/2021 | View on chart |
| MIRM | ▲ Buy | Grant | 21,875 | $0 | 9/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta
Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.
Mirum Pharma's Brevlovitug Hits Phase III Endpoint in Hepatitis Delta. Mirum Pharmaceuticals announced that its drug Brevlovitug met the primary endpoint in a Phase III study for hepatitis delta. The result supports the drug’s potential to become a treatment option for a rare viral infection. The news may influence how investors view the company’s pipeline and future growth prospects.